ADEFOVIR

Antiviral Activity

Used in the treatment of HIV-1 infection in combination with at least two additional antiretroviral agents
Active against susceptible HIV strains, also has some activity against hepatitis B virus and herpes viruses

Pregnancy Risk Factor

Category N/A

Contraindication/Precaution

Hypersensitivity to adefovir or any component
Do not use if pregnant
HIV-infected mothers should not breast-feed in order to avoid transmission to a non-infected newborn
Use caution in the presence of impaired renal function
The safety and effectiveness  have not been established in pediatric patients

Mechanism of Action

Acyclic nucleotide reverse transcriptase inhibitor which interferes with HIV viral RNA dependent DNA polymerase resulting in inhibition of viral replication

Pharmacodynamics/Kinetics

Metabolism: 
N/A
Half-life: 
1.6 hours
Elimination: 
excreted in urine

Dosage

Children:

The safety and effectiveness  have not been established in pediatric patients 

Adults:  

HIV infection:
30-120 mg PO qd
Hepatitis B infection: 
125 mg PO qd

Dosage In Renal Failure

Cr. clearance (ml/min):
N/A
Dialysis
Hemo: N/A
CAPD:  N/A